Alli Return In U.S. Fattens Glaxo’s Consumer Outlook
This article was originally published in The Tan Sheet
Executive Summary
GSK Consumer Healthcare says alli would be available starting Feb. 25 in most stores in the U.S. and Puerto Rico in “improved tamper-evident packaging.” Despite the product’s checkered history, its return marks another boost for Glaxo’s consumer outlook.
You may also be interested in...
Oxytrol For Women Exclusivity Ends Not With Competition, But Label Warning Change
Private labeler Perrigo has eyed launching a generic since FDA approved the 3.9mg oxybutynin transdermal as a first-in-class OTC in 2013. Currently, though, Perrigo says it is "not a big product" and is talking about other prescription OAB products that could be approved for OTC.
Glaxo/Novartis JV Wields ‘Power’ Brands, Switches To Spearhead Global Growth
Glaxo prioritizes seven “power” brands globally and also will invest in boosting sales of 12 “core” brands in its consumer JV with Novartis, says division head Emma Walmsley. The combination of the two firms’ consumer products puts the JV atop the OTC/wellness market in 36 countries.
Glaxo/Novartis JV Wields ‘Power’ Brands, Switches To Spearhead Global Growth
Glaxo prioritizes seven “power” brands globally and also will invest in boosting sales of 12 “core” brands in its consumer JV with Novartis, says division head Emma Walmsley. The combination of the two firms’ consumer products puts the JV atop the OTC/wellness market in 36 countries.